Shares of GSK (GSK) are falling after a Centers for Disease Control and Prevention (CDC) committee shifted its recommendation on Respiratory Syncytial Virus (RSV) vaccination dosages. Yahoo Finance reporter Anjalee Khemlani joins Morning Brief to break down this latest development for GSK and what the CDC announcement could mean for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino.
PHILADELPHIA, June 07, 2024--US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...